New Drug Combo Shows Promise for Aggressive Breast Cancer

Women with triple-negative breast cancer now have new hope after researchers at Baylor College of Medicine discovered a promising treatment for tumors that resist standard chemotherapy.

Triple-negative breast cancer is aggressive and difficult to treat because it lacks the receptors that other breast cancer drugs target. About 15% of all breast cancers fall into this category, and many develop resistance to platinum-based chemotherapy, leaving patients with few options.

The research team started with a discovery that initially seemed discouraging. They found that tumors missing part of a gene called LIG1 were especially resistant to chemotherapy. But Dr. Meenakshi Anurag and her team decided to flip the script and use this weakness to their advantage.

Graduate student Anh M. Tran-Huynh led the effort to understand how these cancer cells repair their DNA. The team tested combinations of drugs that block DNA repair, searching for the right match. They partnered with researchers in London to screen 120 different compounds alongside PARP inhibitors, drugs already approved for other cancers.

The winning combination paired two drugs: olaparib and ceralasertib. Together, they worked far better than either drug alone. In animal models, the combination significantly reduced tumor growth in cancers with LIG1 loss and TP53 mutations.

Why This Inspires

This research represents the kind of problem-solving that transforms cancer care. Rather than accepting chemotherapy resistance as a dead end, the team turned it into a roadmap for better treatment. Their multidisciplinary approach brought together expertise from Texas to London, showing how collaboration accelerates progress.

The breakthrough also offers something patients desperately need: personalized treatment. Doctors can now test tumors for LIG1 levels before choosing therapy. Low LIG1 levels signal that a patient would likely benefit from the drug combination, avoiding ineffective treatments and moving straight to what works.

Dr. Matthew Ellis notes this addresses a critical need in the field. After initial success with PARP inhibitors in certain cancers, progress stalled despite many new drugs being developed. This study shows that matching specific tumor characteristics to targeted drug combinations is the path forward.

The researchers envision LIG1 testing becoming standard practice to identify which patients should receive this treatment in clinical trials. For women facing one of the most challenging cancer diagnoses, this research transforms a marker of resistance into a guide for effective therapy.